156 related articles for article (PubMed ID: 35603756)
1. Systematic review and meta-regression on the duration of LDL-C lowering and major adverse cardiovascular events.
Redel-Traub G; Smilowitz NR; Xia Y; Berger JS
Vasc Med; 2022 Aug; 27(4):375-376. PubMed ID: 35603756
[No Abstract] [Full Text] [Related]
2. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
3. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED
Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
7. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
[TBL] [Abstract][Full Text] [Related]
8. Lipid management for the prevention of cardiovascular disease.
Schaefer JR
Curr Pharm Des; 2011; 17(9):852-60. PubMed ID: 21418030
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol: how low can we go?
Sherbet DP; Garg P; Brilakis ES; Banerjee S
Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530
[TBL] [Abstract][Full Text] [Related]
10. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ
JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571
[TBL] [Abstract][Full Text] [Related]
11. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
12. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
13. Current Choice for LDL-C Lowering in High-Risk CVD Patients Intolerant to Statins.
Fras Z
Curr Vasc Pharmacol; 2021; 19(4):398-402. PubMed ID: 33783343
[No Abstract] [Full Text] [Related]
14. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
15. Statins and the cholesterol mortality paradox.
Nunes JP
Scott Med J; 2017 Feb; 62(1):19-23. PubMed ID: 27889702
[TBL] [Abstract][Full Text] [Related]
16. Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung BM; Lam KS
Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
[No Abstract] [Full Text] [Related]
17. LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y.
Elgendy IY; Elshazly MB
Ann Intern Med; 2021 Apr; 174(4):JC38. PubMed ID: 33819068
[TBL] [Abstract][Full Text] [Related]
18. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants.
Wang N; Fulcher J; Abeysuriya N; Park L; Kumar S; Di Tanna GL; Wilcox I; Keech A; Rodgers A; Lal S
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):36-49. PubMed ID: 31862150
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with statins: lowering of cholesterol or more?].
Rutishauser J
Praxis (Bern 1994); 2006 Jan; 95(4):107-10. PubMed ID: 16485605
[No Abstract] [Full Text] [Related]
20. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
